Browse > Article
http://dx.doi.org/10.7314/APJCP.2014.15.4.1539

Prognostic Value of Serum AFP, AFP-L3, and GP73 in Monitoring Short-term Treatment Response and Recurrence of Hepatocellular Carcinoma after Radiofrequency Ablation  

Wang, Nan-Ya (Department of Cancer Center, First Hospital of Jilin University)
Wang, Cong (Department of Cancer Center, First Hospital of Jilin University)
Li, Wei (Department of Cancer Center, First Hospital of Jilin University)
Wang, Guan-Jun (Department of Cancer Center, First Hospital of Jilin University)
Cui, Guo-Zhen (Department of Cancer Center, First Hospital of Jilin University)
He, Hua (Department of Cancer Center, First Hospital of Jilin University)
Zhao, Heng-Jun (Department of Cancer Center, First Hospital of Jilin University)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.15, no.4, 2014 , pp. 1539-1544 More about this Journal
Abstract
Purpose: Alpha-fetoprotein (AFP), Lens culinaris agglutinin-reactive fraction of AFP (AFP-L3), and Golgi protein 73 (GP73) levels have been widely used as tumor markers for the diagnosis of hepatocellular carcinoma (HCC). The aim of this study was to investigate whether these tumor markers could be used to monitor short-term treatment response and recurrence of HCC in patients undergoing radiofrequency ablation (RFA). Methods: Between July 2012 and July 2013, 53 consecutive patients with newly diagnosed HCC were prospectively enrolled in this study. Among these, 32 patients underwent RFA, after which they were followed up prospectively at the First Hospital of Jilin University in China. Results: AFP, AFP-L3, and GP-73 values pre-RFA were not associated with tumor size, whereas AFP and GP-73 levels tended to be associated with tumor number, the presence of vascular invasion, deterioration of liver function, advanced-stage disease, and a poor performance status. GP-73 levels were dramatically elevated in the patients with hepatitis C-associated HCC. Neither pre-RFA nor 1-month post-RFA tumor marker values were associated with short-term outcome. The short-term recurrence rate of AFP-positive patients measured 1 month post-RFA was obviously higher than that of AFP-negative patients. Conclusions: AFP and GP-73 values were associated with clinical variables representing tumor growth and invasiveness, and the AFP value measured 1 month post-RFA was a strong predictor of short-term recurrence in patients with HCC.
Keywords
AFP; AFP-L3; GP-73; hepatocellular carcinoma; radiofrequency ablation;
Citations & Related Records
Times Cited By KSCI : 3  (Citation Analysis)
연도 인용수 순위
1 Toyoda H, Kumada T, Tada T, et al (2011). Clinical utility of highly sensitive Lens culinaris agglutinin-reactive alphafetoprotein in hepatocellular carcinoma patients with alphafetoprotein <20 ng/mL. Cancer Sci, 102, 1025-31.   DOI   ScienceOn
2 Witjes CD, van Aalten SM, Steyerberg EW, et al (2013). Recently introduced biomarkers for screening of hepatocellular carcinoma: a systematic review and meta-analysis. Hepa Inter, 7, 59-64.   DOI
3 Yamamoto K, Imamura H, Matsuyama Y, et al (2009). Significance of alpha-fetoprotein and des-gamma-carboxy prothrombin in patients with hepatocellular carcinoma undergoing hepatectomy. Ann Surg Oncol, 16, 2795-2804.   DOI
4 Yamamoto K, Imamura H, Matsuyama Y, et al (2010). AFP, AFP-L3, DCP, and GP73 as markers for monitoring treatment response and recurrence and as surrogate markers of clinicopathological variables of HCC. J Gastroenterol, 45, 1272-82.   DOI
5 Yamashita T, Forgues M, Wang W, et al (2008). EpCAM and $\alpha$-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma. Cancer Res, 68, 1451-61.   DOI   ScienceOn
6 Yoshida S, Kurokohchi K, Arima K, et al (2002). Clinical significance of lens culinaris agglutinin-reactive fraction of serum alpha-fetoprotein in patients with hepatocellular carcinoma. Int J Oncol, 20, 305-9.
7 Sterling RK, Wright EC, Morgan TR, et al (2012). Frequency of Elevated Hepatocellular Carcinoma (HCC). Biomarkers in Patients With Advanced Hepatitis C. Am J Gastroenterol, 107, 64-74.   DOI   ScienceOn
8 Saito Y, Shimada M, Utsunomiya T, et al (2012). Prediction of recurrence of hepatocellular carcinoma after curative hepatectomy using preoperative Lens culinaris agglutininreactive fraction of alpha-fetoprotein. Hepatol Res, 42, 887-94.   DOI   ScienceOn
9 Schutte K, Bornschein J, Malfertheiner P (2009). Hepatocellular carcinoma-epidemiological trends and risk factors. Digest Dis, 27, 80-92.
10 Shariff MI, Cox IJ, Gomaa AI, et al (2009). Hepatocellular carcinoma: current trends in worldwide epidemiology, risk factors, diagnosis and therapeutics. Expert Rev Gastroent, 3, 353-67.   DOI   ScienceOn
11 Taketa K, Sekiya C, Namiki M, et al (1990). Lectin-reactive profiles of alpha-fetoprotein characterizing hepatocellular carcinoma and related conditions. Gastroenterology, 99, 508-18.   DOI
12 Tamura Y, Suda T, Arii S, et al (2013). Value of highly sensitive fucosylated fraction of alpha-fetoprotein for prediction of hepatocellular carcinoma recurrence after curative treatment. Dig Dis Sci, 58, 2406-12.   DOI   ScienceOn
13 Tangkijvanich P, Anukulkarnkusol N, Suwangool P, et al (2000). Clinical characteristics and prognosis of hepatocellular carcinoma: analysis based on serum alpha-fetoprotein levels. J Clin Gastroenterol, 31, 302-08.   DOI   ScienceOn
14 Tateishi R, Shiina S, Yoshida H, et al (2006). Prediction of recurrence of hepatocellular carcinoma after curative ablation using three tumor markers. Hepatology, 44, 1518-27.   DOI   ScienceOn
15 Toyoda H, Kumada T, Kaneoka Y, et al (2008). Prognostic value of pretreatment levels of tumor markers for hepatocellular carcinoma on survival after curative treatment of patients with HCC. J Hepatol, 49, 223-32.   DOI   ScienceOn
16 Llovet JM, Bruix J (2000). Early diagnosis and treatment of hepatocellular carcinoma. Best Pract Res Cl Ga, 14, 991-1008.   DOI   ScienceOn
17 Llovet JM, Di Bisceglie AM, Bruix J, et al (2008). Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst, 100, 698-711.   DOI   ScienceOn
18 Hu JS, Wu DW, Liang S, Miao XY (2010). GP73, a resident Golgi glycoprotein, is sensibility and specificity for hepatocellular carcinoma of diagnosis in a hepatitis B-endemic Asian population. Med Oncol, 27, 339-45.   DOI   ScienceOn
19 Ioannou GN, Perkins JD, Carithers RL, (2008). Liver transplantation for hepatocellular carcinoma: impact of the MELD allocation system and predictors of survival. Gastroenterology, 134, 1342-51.   DOI   ScienceOn
20 Mao Y, Yang H, Xu H, et al (2010). Golgi protein 73 (GOLPH2). is a valuable serum marker for hepatocellular carcinoma. Gut, 59, 1687-93.   DOI   ScienceOn
21 Marrero JA, Romano PR, Nikolaeva O, et al (2005). GP73, a resident Golgi glycoprotein, is a novel serum marker for hepatocellular carcinoma. J Hepatol, 43, 1007-12.   DOI   ScienceOn
22 Nouso K, Kobayashi Y, Nakamura S, et al (2011). Prognostic importance of fucosylated alpha-fetoprotein in hepatocellular carcinoma patients with low alpha-fetoprotein. J Gastroen Hepatol, 26, 1195-1200.   DOI   ScienceOn
23 Oka H, Saito A, Ito K, et al (2001). Multicenter prospective analysis of newly diagnosed hepatocellular carcinoma with respect to the percentage of Lens culinaris agglutininreactive alpha-fetoprotein. J Gastroen Hepatol, 16, 1378-83   DOI   ScienceOn
24 Parkin DM, Bray F, Ferlay J, Pisani P (2005). Global cancer statistics, 2002. CA-Cancer J Clin, 55, 74-108.   DOI   ScienceOn
25 El-Serag HB, Rudolph KL (2007). Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology, 132, 2557-76.   DOI   ScienceOn
26 Riener MO, Stenner F, Liewen H, et al (2009). Golgi phosphoprotein 2 (GOLPH2). expression in liver tumors and its value as a serum marker in hepatocellular carcinomas. Hepatology, 49, 1602-09.   DOI   ScienceOn
27 Durazo FA, Blatt LM, Corey WG,, et al (2008). Des-gammacarboxyprothrombin, alpha-fetoprotein and AFP-L3 in patients with chronic hepatitis, cirrhosis and hepatocellular carcinoma. J Gastroen Hepatol, 23, 1541-8.   DOI   ScienceOn
28 Carr BI, Kanke F, Wise M, Satomura S (2007). Clinical evaluation of lens culinaris agglutinin-reactive alphafetoprotein and des-gamma-carboxy prothrombin in histologically proven hepatocellular carcinoma in the United States. Dig Dis Sci, 52, 776-82.   DOI   ScienceOn
29 Chong RJ, Abdullah MS, Hossain MM, Telisinghe PU, Chong VH (2013). Rising incidence of primary liver cancer in Brunei Darussalam. Asian Pac J Cancer Prev, 14, 3473-7.   DOI   ScienceOn
30 Dai X, Zhao HQ, Liu RH, et al (2012). Percutaneous radiofrequency ablation guided by contrast-enhanced ultrasound in treatment of metastatic hepatocellular carcinoma after liver transplantation. Asian Pac J Cancer Prev, 13, 3709-12.   DOI   ScienceOn
31 European Association for the Study of the L, European Organisation for R, Treatment of C (2012). EASL-EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol, 56, 908-43.   DOI   ScienceOn
32 Fujioka M, Nakashima Y, Nakashima O, Kojiro M (2001). Immunohistologic study on the expressions of alphafetoprotein and protein induced by vitamin K absence or antagonist II in surgically resected small hepatocellular carcinoma. Hepatology, 34, 1128-34.   DOI   ScienceOn
33 Fujiyama S, Tanaka M, Maeda S, et al (2002). Tumor markers in early diagnosis, follow-up and management of patients with hepatocellular carcinoma. Oncology, 62, 57-63.   DOI   ScienceOn
34 Garcia M, Ward E, Center M, et al (2007). Global cancer facts & figures 2007. Atlanta, GA: American Cancer Society
35 Abdelgawad IA, Mossallam GI, Radwan NH, Elzawahry HM, Elhifnawy NM (2013). Can glypican3 be diagnostic for early hepatocellular carcinoma among Egyptian patients? Asian Pac J Cancer Prev, 14, 7345-9.   DOI   ScienceOn
36 Bertino G, Ardiri AM, Santonocito MM, Boemi PM (2009). Some patients with HCC haven't abnornormal desgamma- carboxy prothrombin and alpha-fetoprotein levels. Panminerva Medica, 51, 133-4.
37 Bosetti C, Levi F, Boffetta P, et al (2008). Trends in mortality from hepatocellular carcinoma in Europe, 1980-2004. Hepatology, 48, 137-45.   DOI   ScienceOn
38 Block TM, Comunale MA, Lowman M, et al (2005). Use of targeted glycoproteomics to identify serum glycoproteins that correlate with liver cancer in woodchucks and humans. PNAS, 102, 779-84.   DOI   ScienceOn